- Specialized Toxicology Assessments
- Toxicokinetic Analyses
Given the intricate nature of the pathological mechanisms underlying rare blood disorders, the development of therapeutics to address them encounters a myriad of distinctive challenges. Leveraging a wealth of expertise and cutting-edge technologies, our company delivers inclusive preclinical research services dedicated to the drug development of rare blood disorders, tailored to fulfill your specific research requirements.
In drug development, preclinical research is the stage of research that takes place before human clinical trials commence. Typically conducted in experimental animals, preclinical research aims to evaluate the pharmacodynamics (PD), pharmacokinetics (PK) and toxicology of drug candidates, laying the groundwork for subsequent clinical trials. This data is crucial in determining whether a drug is ready to advance to the clinical trial phase, aiding in improving the success rate of drug development and minimizing potential risks.
Pharmacodynamics (PD)
Pharmacodynamics (PD) focuses on how drugs interact with the body at functional and molecular levels, primarily investigating the effects of drugs on biological systems, including their mechanisms of action, potency, and efficacy.
Pharmacokinetics (PK)
Pharmacokinetic (PK) studies are essential to describe how a drug is absorbed, distributed, metabolized, and excreted from the body. PK assessments provide important information about a drug's bioavailability, half-life, clearance, and tissue distribution.
Toxicology
Toxicology evaluates the safety and potential adverse effects of candidate drugs on biological systems. These studies are designed to identify toxic effects, determine the dose levels at which toxicity occurs, and assess the overall safety of the drug.
Fig. 1 The drug discovery and development process, as well as the main contents of preclinical research. (Wu, Fengxu, et al., 2020)Due to the unique challenges presented by rare blood disorders, preclinical research plays a critical role in the development of therapeutics for these conditions. Preclinical studies can help researchers uncover the potential molecular and cellular mechanisms of rare blood disorders, providing important insights into disease pathogenesis and potential therapeutic targets. By screening and evaluating potential candidate drugs in preclinical models, researchers can identify compounds that show efficacy in treating rare blood disorders and conduct comprehensive assessments of their safety and effectiveness.
Applications of Preclinical Research
At our company, we specialize in preclinical research dedicated to advancing therapy development for rare blood diseases. Through the meticulous creation of precise in vitro and animal models, we conduct comprehensive pharmacodynamic (PD), pharmacokinetics (PK), and toxicology studies. Our unwavering commitment ensures the efficacy and safety of therapies, paving the way for our clients to seamlessly introduce innovative therapeutics to market.
In Vivo Pharmacokinetic Studies
In Vivo Pharmacokinetic Studies
Our company provides a variety of models for preclinical research of rare blood disease drugs, including cell-based models, organoid models, genetically engineered models, surgical models, induced disease models and humanized animal models. These models serve as controlled experimental platforms that play a pivotal role in expediting the progress of novel drug development and furnishing robust backing for forthcoming clinical trials.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)